Sign In
Buy ASRT
$23.47
+0.0200 (+0.0853%)
At Close: Jun 03, 2026
Are Medical Stocks Lagging Assertio (ASRT) This Year?
10:41am, Monday, 16'th Feb 2026
Here is how Assertio (ASRT) and Aura Biosciences, Inc. (AURA) have performed compared to their sector so far this year.
Wall Street Analysts See a 230.56% Upside in Assertio (ASRT): Can the Stock Really Move This High?
10:55am, Monday, 02'nd Feb 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 230.6% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the posi
Wall Street Analysts Think Assertio (ASRT) Could Surge 249.87%: Read This Before Placing a Bet
10:55am, Friday, 16'th Jan 2026
The consensus price target hints at a 249.9% upside potential for Assertio (ASRT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
10:41am, Wednesday, 14'th Jan 2026
Here is how Assertio (ASRT) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Short Interest in Assertio Holdings, Inc. (NASDAQ:ASRT) Drops By 92.8%
03:52am, Wednesday, 14'th Jan 2026
Assertio Holdings, Inc. (NASDAQ: ASRT - Get Free Report) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 285,110 s
Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements
04:15pm, Monday, 12'th Jan 2026
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial
01:45pm, Friday, 09'th Jan 2026
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule
Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split
04:30pm, Monday, 22'nd Dec 2025
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorpor
Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates
07:56pm, Monday, 10'th Nov 2025
Assertio (ASRT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.03 per share a year ago.
Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript
06:21pm, Monday, 10'th Nov 2025
Assertio Holdings, Inc. ( ASRT ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Mark L. Reisenauer - CEO & Director Paul Schwichtenberg - Executive VP & Chief Transformation
Assertio Reports Third Quarter 2025 Financial Results
04:13pm, Monday, 10'th Nov 2025
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering different
Assertio Announces Leadership Transition
09:15am, Tuesday, 28'th Oct 2025
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: FINAL DEADLINE in Securities Lawsuit– Hagens Berman
04:37pm, Tuesday, 23'rd Sep 2025
SAN FRANCISCO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development off
PHILADELPHIA , Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spect
New Strong Sell Stocks for September 23rd
06:06am, Tuesday, 23'rd Sep 2025
ATS, ASRT and DBVT have been added to the Zacks Rank #5 (Strong Sell) List on September 23, 2025.
